Orphazyme A/S (ORPHA.CO)

2.1000 -0.1280 (-5.75%) At close: 04:50PM CEST

Orphazyme A/S

Ole MaalOees Vej 3
Copenhagen 2200
Denmark
45 39 17 82 72
https://www.orphazyme.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 62

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA	CEO & CFO	3.24M	N/A	1969
Jennifer Jean McCann	Pres of Orphazyme US, Inc.	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Corporate governance

Orphazyme A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.